XNCR vs. MNKD, PRTA, MIRM, ABCL, BLTE, GMTX, COLL, DCPH, PIRS, and MGNX
Should you be buying Xencor stock or one of its competitors? The main competitors of Xencor include MannKind (MNKD), Prothena (PRTA), Mirum Pharmaceuticals (MIRM), AbCellera Biologics (ABCL), Belite Bio (BLTE), Gemini Therapeutics (GMTX), Collegium Pharmaceutical (COLL), Deciphera Pharmaceuticals (DCPH), Pieris Pharmaceuticals (PIRS), and MacroGenics (MGNX). These companies are all part of the "pharmaceutical preparations" industry.
MannKind (NASDAQ:MNKD) and Xencor (NASDAQ:XNCR) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, community ranking, valuation, analyst recommendations, dividends, institutional ownership, profitability, media sentiment and earnings.
MannKind has a beta of 1.28, meaning that its share price is 28% more volatile than the S&P 500. Comparatively, Xencor has a beta of 0.76, meaning that its share price is 24% less volatile than the S&P 500.
MannKind has higher revenue and earnings than Xencor. MannKind is trading at a lower price-to-earnings ratio than Xencor, indicating that it is currently the more affordable of the two stocks.
In the previous week, Xencor had 1 more articles in the media than MannKind. MarketBeat recorded 1 mentions for Xencor and 0 mentions for MannKind. MannKind's average media sentiment score of 1.76 beat Xencor's score of 0.00 indicating that Xencor is being referred to more favorably in the news media.
MannKind presently has a consensus price target of $8.00, indicating a potential upside of 89.13%. Xencor has a consensus price target of $36.00, indicating a potential upside of 80.18%. Given Xencor's stronger consensus rating and higher probable upside, analysts plainly believe MannKind is more favorable than Xencor.
49.6% of MannKind shares are owned by institutional investors. 3.0% of MannKind shares are owned by company insiders. Comparatively, 5.0% of Xencor shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
MannKind received 81 more outperform votes than Xencor when rated by MarketBeat users. However, 72.85% of users gave Xencor an outperform vote while only 59.83% of users gave MannKind an outperform vote.
MannKind has a net margin of -6.00% compared to MannKind's net margin of -74.90%. Xencor's return on equity of 0.00% beat MannKind's return on equity.
Summary
MannKind beats Xencor on 11 of the 18 factors compared between the two stocks.
Get Xencor News Delivered to You Automatically
Sign up to receive the latest news and ratings for XNCR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding XNCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
